The Alexandria Real Estate Equities-backed regenerative medicine developer increased its total funding to $147m with a round led by Perceptive Advisors.

Frequency Therapeutics, a US-based small-molecule drug developer backed by life sciences real estate investment trust Alexandria Real Estate Equities, completed a $62m series C round yesterday.

Hedge fund sponsor Perceptive Advisors led the round, investing alongside Mizuho Securities Principal Investment, a subsidiary of investment banking firm Mizuho Securities, as well as RTW Investments, Polaris Founders Capital, Deerfield Management, Taiwania Capital Management, Axil Capital and CoBro Ventures.

Frequency is developing therapeutics that are intended to create functional tissues and organs by…